Posts by: Alice Melão

Alice Melão

September 24, 2018

Investigational Cancer Vaccine Galinpepimut-S Receives Orphan Drug Status in EU for Multiple Myeloma

News

SELLAS Life Sciences’ lead therapy candidate galinpepimut-S (GPS) received orphan medicinal product designation from the European Medicines Agency for the treatment of multiple myeloma patients, according to a press release. ... Read more

July 27, 2018

Karyopharm Seeks Selinexor’s Accelerated Approval in US for Heavily Treated Myeloma Patients

News

Karyopharm Therapeutics is seeking accelerated approval for its investigational therapy selinexor in the United States as a treatment for heavily treated multiple myeloma patients. The company has begun the ... Read more

July 11, 2018

Early Relapse in Multiple Myeloma Linked to Greater Economic Burden in US

News

Multiple myeloma patients whose cancer progresses early after first-line therapy have a greater economic burden compared to those whose disease progresses later, a recent study shows. The findings highlight ... Read more

June 18, 2018

Companies Collaborating to Use ClonoSEQ Assay in Multiple Myeloma Trials Testing Isatuximab

News

Adaptive Biotechnologies is collaborating with Sanofi to use its clonoSEQ Assay for measuring minimal residual disease in multiple myeloma patients receiving isatuximab, a treatment candidate for newly diagnosed, relapsed or refractory multiple ... Read more

April 23, 2018

New Method of Classifying Malignant Myeloma Cells Improves Outcomes, Study Finds

News

A new method that selects and isolates malignant myeloma cells based on their size and molecular markers enables more precise detection of chromosomal abnormalities, University of Southern California researchers ... Read more

April 20, 2018

P-BCMA-101 Shows Early Effectiveness in First Multiple Myeloma Patients Treated in Phase 1 Trial

News

P-BCMA-101, Poseida Therapeutics’ CAR T-cell therapy, is safe and effective in relapsed or refractory multiple myeloma patients, results from the first three patients enrolled in a Phase 1 trial show. ... Read more

April 18, 2018

Seattle Genetics’ Investigational Therapy Fares Well in Multiple Myeloma Animal Models

News

A new antibody targeting the BCMA protein — called SEA-BCMA — has shown promising effectiveness and safety results in animal models of multiple myeloma, making it a strong candidate ... Read more

April 11, 2018

China FDA Prepares to Review Evomela for Approval in Multiple Myeloma Treatment

News

Multiple myeloma patients in China may soon have access to an injectable formulation of melphalan, called Evomela, as the China Food and Drug Administration (CFDA) prepares to review CASI ... Read more

April 2, 2018April 2, 2018

Bluebird Bio and Celgene Partner to Advance bb2121, Potential Multiple Myeloma CAR T-cell Therapy

News

The investigational therapy bb2121, a possible treatment for relapsed or refractory multiple myeloma patients, is advancing in clinical testing under a recently announced partnership between bluebird bio and Celgene. The companies ... Read more

February 26, 2018February 26, 2018

Revlimid Combo Treatment Improved Survival in Newly-diagnosed Myeloma Patients in Phase 3 Trial

News

Newly diagnosed multiple myeloma patients unable to undergo stem cell transplants lived significantly longer without their disease progressing when given continuous treatment with Revlimid (lenalidomide) and low-dose dexamethasone, compared ... Read more